已收盘 02-06 16:00:00 美东时间
+0.127
+14.75%
Alpha Tau Medical Ltd has initiated its U.S. multi-center pancreatic cancer pilot study, IMPACT, combining Alpha DaRT with chemotherapy for patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma. Pancreatic cancer is the third leading cause of cancer death in the U.S., with 87% of patients inoperable at diagnosis. Alpha DaRT's localized alpha radiation aims to improve treatment outcomes for high-unmet-need patients. T...
2025-09-02 12:30
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau"...
2024-05-01 20:30
- The overview presentation will review some of the Company's recent achievemen...
2023-12-20 22:15
Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) was the target of a signific...
2023-03-08 07:23
JERUSALEM, March 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Ta...
2023-03-01 21:36
Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) saw a large decrease in shor...
2023-01-22 12:11
Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) was the target of a signific...
2022-12-31 15:12
Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) was the target of a signific...
2022-12-31 15:11
JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DR...
2022-12-13 21:06
JERUSALEM, May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (NASDAQ:DRTS) (NASDAQ:DRTSW), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first
2022-05-23 21:06